Background: Primary liver non-Hodgkin's lymphomas have peculiar clinical and biological patterns. This study correlates these patterns with pathology and outcome.
Introduction
Liver is one of the most frequently involved organs in disseminated non-Hodgkin's lymphomas (NHLs), and may be detected in up to 40% of patients at the time of initial staging [1] . By contrast, primary liver NHLs are rare and account for less than 1% of NHLs. Less than 100 cases of primary liver NHLs were reported in Medline indexed literature in 1998 [2] , and only seven series include more than three patients [3] [4] [5] [6] [7] [8] [9] .
The diagnosis of primary liver NHL is often unsuspected before biopsy or surgical resection. Indeed, clinical presentation is variable [10] . A liver mass may be disclosed by echography in a patient with abdominal pain, while other patients may be referred for liver transplantation for acute liver failure. Patients have been treated by surgical resection, radiotherapy, chemotherapy, or by a combination of these treatments. Because of the low number of reported cases, the variability of the clinical presentation and of the treatment, the prognosis and the optimal treatment of patients with primary liver NHL are still debated.
We present herein a series of eight patients with primary liver NHL treated in our institution over a 20-year period. Our data, and the analysis of the other published series, suggest that patients with primary liver NHL should be classified in two distinct clinical entities, nodular and diffuse liver infiltration. Most lymphomas with nodular infiltration of the liver are of large B-cell type, and have a good prognosis, and may benefit from an anthracyclin-based chemotherapy. Patients with diffuse liver infiltration have a poor prognosis.
Patients and methods

Patients
Patients with histologically proven liver lymphomatous infiltration were retrieved from the files of the pathology department of Paul Brousse hospital. Lymphoproliferative disorders (28 cases), occurring after liver transplantation and Hodgkin's lymphomas (23 cases), were excluded from the study. Over a 20-year period, from January 1979 to December 1999, slides and medical records from 51 patients were available for the study. Histological samples and clinical records of these patients were reviewed. Inclusion criteria were as previously published (2)-I) symptoms mainly caused by liver involvement at time of diagnosis: 2) absence of distant lymphadcnopathy, palpable clinically at time of presentation or detected during staging radiological studies, 3) absence of leukemic blood picture in peripheral blood film. Lymphomatous infiltration of lymph node of the hepatic hilum. of the spleen and/or of the bone marrow at time of diagnosis were not exclusive. Altogether, 8 out of the 51 patient (16%) fit these criteria. The 43 other patients had an extra-hepatic dissemination. Abbreviations: HM -hepatomegaly; SM -splenomegaly; ALAT -alanine aminotransferase; GGT -g-glutamyl-transpeptidase; ALP -alkaline phosphatase; PT -prothrombin time; LDH -Lactic dehydrogenase; M -male; F -female; N -within normal range; N+ -less than twice the normal value; 2N+ -more than twice the normal value: NA -not available.
Pathology
Diagnosis of NHL was established, according to R.E.A.L [II] and WHO [12] classifications on paraffin wax embedded tissue from either needle biopsies (n -7) or surgical liver specimens (n = 1). Histological analysis was performed on hematoxylin and eosin (H&E) and Giemsastained slides.
Immunohistochemistry was performed on four urn thick sections of paraffin-embedded liver samples with a three step avidine-biotin technique according to manufacturer's instruction (LSAB2, Dako, Copenhagen, Denmark). The primary antibodies were anti-CD5 (4C7, Novocastra Laboratories Ldt. Newcastel uponTyne, UK), CD20 (L26, Dako), Bcl-2 (Dako), Mib-I (Dako), p53 DO-7 (Dako),TIA-l (Coulter, Hialeah, FL) mouse monoclonal antibodies, and anti-CD3 (Dako) rabbit polyclonal antibodies. Immunostaining was also performed on frozen sections of T-cell lymphomas with deltaTCRI (T-cell Sciences, Cambridge, Massachusetts), betaFl (T-cell Sciences).
Bibliography and statistics
The data analyzed in this report was accrued through a review of the English language medical indexed literature from January 1976 to December 1999. As many individual case reports were lacking important biological and/or clinical data, we only used data from series including more than two cases of primary liver NHL [3] [4] [5] [6] [7] [8] [9] for statistical analysis. Altogether, data from 62 patients published in eight series (including ours), were analyzed. All but two [6, 8] of these eight series were from a single institution.
Cumulative survival for patients with primary liver NHLs were estimated by the Kaplan-Meier method based upon the duration of survival specified for each patient in each report included within our review. The survival functions were compared with the log rank test. Statistical analysis was performed with StatView F-4.5 (SAS Institute, Cary, North Carolina).
Results
The main clinical features of the patients at presentation are summarized in Table 1 . Six patients were female and two were male, with an age ranging from 25 to 73 years (median 50 years). All the patients had a liver enlargement at physical examination, four also had a splenomegaly. Six patients had negative serologies for B-and C-hepatitis virus, one was virus B positive (#3) and one was not tested (#1).
Clinical presentation
For three patients, liver involvement consisted in nodules (Table 1) . Two had no relevant clinical history, and one had a virus B-related cirrhosis (#3). Physical examination revealed hepatomegaly in all cases, jaundice in one and severe upper digestive bleeding and sepsis in another. This latter patient was admitted in an intensive care unit. Liver lymphomatous mass were hyperechogenic in all cases. The liver nodule was unique in all cases. Liver enzymes were elevated in two cases.
The five other patients had an hepatomegaly without any detectable nodule with either echography or tomography ( Table 1) . One of them (#1) had been treated since the age of 1.5 for a primary immune B cell deficiency by injections of human gammaglobulines. In 1979, at the age of 25 years the patient was admitted for fever and weight loss without evidence of infection. At this time, she had a hepatosplenomegaly. A splenectomy (spleen weight 1.5 kg) and a liver biopsy were performed. Patient #7 received a kidney transplantation six years before admission. The three other patients had no relevant clinical history. The five patients presented with B symptoms (fever, night sweats and/or weight loss) and hepatomegaly. Liver enzymes were elevated in all cases, and two patients (#4 and #7) had altered liver function, and were initially admitted in an intensive care unit.
Pathology
The three patients with liver nodules had a diffuse large cell lymphoma of B-cell phenotype. The tumors had a destructive growth pattern, without detectable residual portal tracts inside. Tumor cells had a centroblastic morphology (Figure la), and were positive for CD20 and negative for CD3 and CDS. Only a few (less than 5%) tumor cells were Bcl-2 positive. The tumor cells were p53 positive in one case (#2) and negative in the two others.
Among patients with diffuse liver infiltration, three had a T-cell lymphoma (#1, #6 and #7). In these A* Figure 1 . Histology of primary liver lymphomas; (a) nodular infiltration of the liver corresponding to a large B-cell lymphoma: liver parenchyma is destroid, and replaced by the tumour proliferation; the tumour was monomorphic, and consisted in an area of large lymphoma cells with centroblastic morphology (H&S, original magnification x400); (b) diffuse infiltration of the liver corresponding to a yb T-cell lymphoma: liver architecture was preserved with liver-cell plates and sinuses; Imphoma cells had a small size and a dense nucleus, they were mainly localized within hepatic sinuses (arrowheads) (H&S, original magnification x400).
cases, infiltration and dilatation of hepatic sinusoids were predominant (Figure lb) . Tumor cells were small to medium sized. Tumor cells were CD3 positive, CD20 negative and contained numerous cytotoxic granules (TIA-1 positive). A frozen liver biopsy was available for patient #6, and tumor cells were positive for 5TCR1 and negative for (3F1, thus confirming the diagnostic of y6 T-cell lymphoma. For the two other patients, no frozen samples were available, and although the predominant sinusoid infiltration was suggestive of a y5 origin of these T-cell lymphomas, we failed to demonstrate it. Necropsy was performed in patient #1, one year after the initial liver biopsy. It revealed an enlarged liver (5.3 kg) without nodules, and confirmed the predominant sinusoid infiltration by T-lymphoma cells.
The two other patients with diffuse liver infiltration had a large cell lymphoma of B-cell phenotype. Tumor growth pattern was not destructive in both cases. For patient #4 tumor infiltration was limited to portal tracts, while tumor cells were present in portal tract as well as in sinusoids in patient #8. In both cases, lymphoma cells were positive for CD20 and negative for CD3, CD5 and p53. Bcl-2 was expressed by more than 80% of tumor cells in case #4, and not expressed by tumor cells in case #8.
Treatments and outcome
Over a 20 years period, treatments of the patients of our series was highly variable ( Table 2) . One of the patients with nodular liver lymphoma (#3) died a few days after liver biopsy. The two other (#2 and #5) were treated with anthracyclin-containing regimens. For one chemotherapy was given after surgical resection of the tumor. Both patients achieved a long-lasting complete remission. Two out of the three patients with diffuse liver infiltration by T-cell lymphoma did not receive specific treatment. Indeed, for the older case (#1), the diagnosis of lymphoma was performed retrospectively. The patient was treated with anti-infectious agents and corticoids, and she died 12 months later with multi-organ failure. Patient #7 died four days post diagnosis from multiorgan failure. Patient #6 was treated with one cycle of an anthracyclin-containing regimen and 8 cycles of oxaliplatin and cytarabine. An autologous bone marrow transplantation performed after BEAM conditioning regimen. This patient was alive without evidence of disease 17 months after diagnosis.
One of the two patients with diffuse liver infiltration by a B-cell lymphoma died the day of the liver biopsy from acute liver failure. The other patient achieved partial remission after an anthracyclin-containing chemotherapy, and finally died of tumor progression despite salvage therapy.
Survival analysis
Although our series was one of the largest published, it was not possible to perform a survival analysis. We thus analyzed the data available from the other published series with our own patients. Altogether 62 patients were included. Nodular infiltration was diagnosed in 41 cases. Fourteen of them (34%) were dead 0 to 1.6 years after diagnosis, while 27 were alive 0.1 to 12 years after diagnosis. The one-year and three-year survivals were 70% and 57%, respectively (Figure 2a) . Diffuse infiltration was diagnosed in 21 patients of the largest published series. Most of them (81%) died, and death occurred during the first year following diagnosis in 3/4 of them. Prognosis of patients with diffuse liver infiltration was worse than that of patients with nodular liver infiltration (P = 0.0033).
As anthracyclin-containing chemotherapies are used to treat the majority of patients with aggressive NHLs, we tried to determine whether this type of treatment was Abbreviations. B symptoms -fever, night sweas and/or weight loss; IPI -international prognostic index; Spl -sleen; BM -bone marrow, Anthra -anthracycline containing chemotherapy; ABMT -autologous bone marrow transplantation; AraC -aracytin; Oxaly -oxalyplatin; CR -complete remission: DOD -dead of disease. " Patients #2, 5 and 6 were in CR without treatment for 135. 44 and 6 months, respectively, after last follow-up. useful for patients with nodular primary liver NHLs. Fourteen out of the forty-one patients with nodular liver infiltration received an anthracyclin-containing chemotherapy. Survival of these patients (Figure 2b ) was significantly better than that of the patients receiving other treatments (P < 0.0001). The number of patients with diffuse liver infiltration and clinical information concerning the treatment was not sufficient to test the value of anthracyclin in this subset of patients.
Discussion
We present herein a series of eight patients with primary liver non-Hodgkin's lymphoma, treated in our institution over a 20-year period. According to the type of liver infiltration at presentation, we were able to classify the patients in two groups. Nodular liver infiltration corresponded to high grade B-cell lymphomas, and diffuse liver infiltration corresponded to either T-or B-cell lymphomas. Survival analysis of the published cases of primary liver lymphomas confirmed the clinical interest of separating these patients in two groups. Indeed, those with nodular infiltration of the liver had a significantly better prognosis than those with diffuse infiltration. Nodular infiltration accounts for 66% of the 62 cases of primary NHL of the liver reported in the series ( [3] [4] [5] [6] [7] [8] [9] , and our series). The mean age of the 41 patients with nodular liver NHL infiltration was 53 years (median 51, range 21-87). The male/female sex ratio was 26/15. As in our series, patients with nodular liver infiltration usually presented with abdominal pain and/or hepatomegaly. Fever, night sweats or weight loss (i.e., B symptoms) were present in 41% of the cases. The liver mass was solitary in most cases (71%). All patients had normal a fetoprotein, and 86% had elevated serum levels of lactic dehydrogenase. Several pathological classifications have been used since the first reported cases in 1969 [13] . However, as in our series, most cases (76%) corresponded to diffuse large cell lymphomas, and phenotype was B cell in the recent series.
Diffuse liver lymphomatous infiltration was reported in 21 (34%) out of the 62 patients of the published series. The mean age of these patients was 57 years (median 54, range 25-85). The male/female sex ratio was 12/9. Most patients (19 of 21) had B signs at initial presentation. All had an hepatomegaly, and half (6 of 13) of the patients from single center series had a splenomegaly.
Bone marrow was involved in half the cases (6 of 11). All the patients had normal tx fetoproteins, and most of them had elevated serum levels of lactic dehydrogenase. Gaulard and al. described a subtype of lymphoma, with predominant hepatic and splenic infiltration: y5 T-cell lymphoma [14] [15] [16] . These NHL mainly involve middleaged women, some of whom may have received immunosuppressive drugs (organ transplantation, Hodgkin's lymphoma,...). Liver infiltration predominates in the sinuses and tumor cells express the yS T-cell receptor. Three patients in ours series had the clinicopathological features of y § T-cell lymphomas, two of which were immuno-deficient (primary hypogammaglobulinemia and renal transplantation). Other histological types of lymphoma may be responsible for a primary diffuse liver infiltration, some of which may be of B-cell phenotype [17] as were the two other cases of our series.
Prognosis of primary liver lymphoma is still deatable, mainly because of the low number of published cases, the recent improvement of diagnostic tools (i.e., immunohistochemistry and molecular biology), the high variability of treatments and the absence of prospective studies. Our statistical analysis of the data provided by published series (including ours), shows that prognosis of patients with either nodular or diffuse infiltration of the liver is different (P = 0.0033). The one-year and three-year survivals were respectively 70% and 57% for patients with nodular infiltration, and 38% and 18% for patients with diffuse infiltration. Furthermore, patients with nodular primary liver NHL had a better prognosis when treated with an anthracyclin-containing chemotherapy (P < 0.0001). This important survival difference may be partly due to the fact that the patients with the worse initial performance status did not receive an anthracyclin-containing chemotherapy. However, half of the patients without anthracyclin treatment died more than three months after diagnosis. The 62 patients from these published series were treated over a period of 20 years. During this period of time, supporting cares have improved. However, the survival was not related to the date of diagnosis in our series, nor with the date of publication in other series. We thus conclude that patients with nodular infiltration of the liver should be treated with an anthracyclin-containing chemotherapy.
Lymphomatous diffuse liver infiltration may be associated with an alteration of liver functions, and may eventually be responsible for acute liver failure [18, 19] . Indeed, two patients from our series and one from another group [9] presented with acute liver failure and rapidly died. In a recently published series of 18 patients with acute liver failure caused by tumor infiltration, 9 were related to a NHL [20] , most of which were already diagnosed. The diagnosis of primary liver infiltration by lymphoma is often unsuspected, and a patient may be referred for liver transplantation [21] , or diagnosis may be performed postmortem [18, 22] . Therefore, patients presenting with acute liver failure and hepatomegaly should undergo a liver biopsy.
In conclusion, primary liver lymphomas are rare tumors. A nodular liver lymphomatous infiltration should be suspected in either cirrhotic or non-cirrhotic patients with hypovascularized liver nodule(s), normal alphafetoprotein and elevated serum lactic dehydrogenase. It usually corresponds to a large B-cell lymphoma. These patients may benefit from anthracyclin-based chemotherapy. Diffuse liver lymphomatous infiltration should be suspected in patients with hepatic or hepatosplenic enlargement, B symptoms (i.e., weight loss, night sweats or fever) and elevated liver enzymes and/or altered liver functions. The bad prognosis of these patients may be in part related to the diagnostic delay. An early liver biopsy of these patients might allow initiation of a specific treatment, before liver failure and/or lymphoma dissemination.
